# Metagenomi Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Metagenomi Therapeutics, Inc.). ## Overview Metagenomi Therapeutics, Inc. is an in vivo genome editing company developing curative genetic medicines using proprietary editing systems discovered from metagenomic science. The company focuses on advancing a small set of higher-probability programs for diseases with well-understood biology, while partnering on selected programs and enabling technologies. ## Products & services • In vivo genome editing therapeutic programs • Proprietary metagenomics-derived gene editing tools • CRISPR/Cas-adjacent nuclease platforms • Collaboration and license agreements for partnered programs • cGMP manufacture of clinical-grade nucleases and mRNA • LNP-formulated genome editing constructs - **Wholly owned genome editing programs** (0%) — Internal therapeutic programs using the company's signature gene-editing systems for specific disease targets. - **Collaborative research and license programs** (100%) — Partnered programs where the company earns collaboration revenue from research, development, and licensing activities. - **Genome editing platform technologies** (0%) — Proprietary editing tools, discovery capabilities, and enabling technologies used to build future medicines. - **Manufacturing and process capabilities** (0%) — cGMP production of clinical-grade nucleases and mRNA to support internal and collaboration programs. - In vivo genome editing therapeutic programs - Proprietary metagenomics-derived gene editing tools - CRISPR/Cas-adjacent nuclease platforms - Collaboration and license agreements for partnered programs - cGMP manufacture of clinical-grade nucleases and mRNA - LNP-formulated genome editing constructs ## Customers The company’s direct customers are pharmaceutical and biotechnology collaborators that license its genome editing technologies or fund joint research and development. It also serves future patients indirectly through therapeutic development, but it has not yet generated product sales and currently monetizes mainly through collaboration revenue. Strategic partners such as Ionis, Moderna (historically), Affini-T, and technology licensors are central to its business model. - **Pharmaceutical collaborators** (primary) — Large pharma partners that pay for access to genome editing tools, research services, and potential product rights. - **Biotechnology partners** (primary) — Smaller biotech companies that collaborate on discovery and development using the company's editing platforms. - **Technology and manufacturing partners** (secondary) — Licensors and CMOs that provide LNP, gRNA, DNA template, and manufacturing support for programs. - **Future therapeutic end users** (emerging) — Patients with genetic diseases targeted by the company's in vivo editing programs, once products are approved. - Pharma collaborators that license genome editing technology - Biotech partners funding joint research and development - Strategic partners seeking single-target or platform access - Future patients in rare or genetically defined diseases - Technology licensors and CMO partners supporting development ## Geography The company is headquartered in Emeryville, California and operates primarily from the United States. Its business is currently research- and collaboration-driven, so geography matters more through where R&D, manufacturing, and partner activity occur than through product sales. It is expanding a cGMP manufacturing facility in the U.S. and relies on third-party suppliers and collaborators that may be located domestically or internationally. - Headquartered in Emeryville, California - Core operations and R&D are U.S.-based - cGMP manufacturing facility is being expanded in the U.S. - Third-party CMOs support gRNA and DNA template supply - No disclosed country revenue split; no product sales yet ## Strategy Management is prioritizing a narrower set of lead programs with the highest probability of success, focusing on disease areas with clear biology and regulatory paths. The company is also strengthening enabling capabilities, including cGMP manufacturing and selective licensing, to support both wholly owned and partnered development while preserving capital. - **Pipeline reprioritization** (short-term) — Concentrates resources on programs with the best chance of technical and regulatory success. - **Partnership-led development** (medium-term) — Collaborations provide non-dilutive funding, validation, and access to complementary expertise. - **Manufacturing capability buildout** (medium-term) — Internal cGMP capacity reduces dependence on third parties for critical clinical-grade materials. - Reprioritize pipeline toward highest-probability programs - Focus on well-understood diseases and clearer regulatory paths - Advance lead in vivo genome editing assets - Use collaborations to share development risk and fund R&D - Build internal manufacturing capability for critical materials - Maintain financial discipline and preserve runway ## Risks The company faces the typical risks of an early-stage biotech: clinical failure, regulatory delay, and the need for substantial additional capital before any product sales. Its model also depends on collaborators, third-party manufacturers, and strong intellectual property protection, while genome editing adds safety, delivery, and reputational risk if adverse events emerge. - **Clinical and regulatory failure** [critical] — Programs may not show sufficient safety or efficacy, and approval pathways can be lengthy and uncertain. - **Capital dependence and dilution** [high] — The company has incurred significant losses and expects to need external funding to continue development. - **Collaboration dependence** [high] — Revenue and development progress rely on partners that may terminate, slow, or dispute agreements. - **Third-party manufacturing and supply chain** [high] — The company relies on CMOs and suppliers for gRNA, DNA templates, and future commercial supply. - **Intellectual property protection** [high] — Genome editing is highly competitive and difficult to defend without broad, enforceable IP. - **Safety and post-approval obligations** [high] — Adverse events could trigger REMS, label restrictions, litigation, or loss of market acceptance. - No product revenue yet; future sales depend on clinical success - Needs additional capital and may dilute shareholders - Collaborations may fail or create strategic conflicts - Third-party manufacturing can disrupt supply and timelines - Genome editing safety or REMS requirements could limit adoption - IP disputes or weak protection could erode competitive position ## Accounting The most important accounting issue is collaboration revenue recognition, since all revenue to date comes from partner agreements rather than product sales. Investors should also watch stock-based compensation, lease accounting for lab and office space, and valuation judgments around deferred tax assets and uncertain tax positions, all of which can materially affect reported losses and balance sheet values. - **Collaboration revenue recognition** — Can create uneven quarterly revenue and affect comparability - **Stock-based compensation** — Increases operating losses without immediate cash outflow - **Lease accounting** — Creates right-of-use assets and lease liabilities that affect leverage metrics - **Deferred tax assets and uncertain tax positions** — Can lead to valuation allowances and earnings volatility - Collaboration revenue timing affects quarterly results - No product sales yet, so revenue is milestone/contract driven - Stock-based compensation is a major non-cash expense - Lease accounting affects lab and office obligations - Deferred tax asset valuation depends on future profitability - Uncertain tax positions and estimates can change reported results --- *Last updated: 2026-04-28T20:27:05.136071+00:00*